Stockreport

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine [Seeking Alpha]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 1 [Read more]